Development of autoantibodies before the clinical onset of systemic lupus erythematosus - PubMed (original) (raw)
. 2003 Oct 16;349(16):1526-33.
doi: 10.1056/NEJMoa021933.
Affiliations
- PMID: 14561795
- DOI: 10.1056/NEJMoa021933
Free article
Development of autoantibodies before the clinical onset of systemic lupus erythematosus
Melissa R Arbuckle et al. N Engl J Med. 2003.
Free article
Abstract
Background: Although much is known about the natural history of systemic lupus erythematosus (SLE), the development of SLE autoantibodies before the diagnosis of the disease has not been extensively explored. We investigated the onset and progression of autoantibody development before the clinical diagnosis.
Methods: The Department of Defense Serum Repository contains approximately 30 million specimens prospectively collected from more than 5 million U.S. Armed Forces personnel. We evaluated serum samples obtained from 130 persons before they received a diagnosis of SLE, along with samples from matched controls.
Results: In 115 of the 130 patients with SLE (88 percent), at least one SLE autoantibody tested was present before the diagnosis (up to 9.4 years earlier; mean, 3.3 years). Antinuclear antibodies were present in 78 percent (at a dilution of 1:120 or more), anti-double-stranded DNA antibodies in 55 percent, anti-Ro antibodies in 47 percent, anti-La antibodies in 34 percent, anti-Sm antibodies in 32 percent, anti-nuclear ribonucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent. Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibodies were present earlier than anti-Sm and anti-nuclear ribonucleoprotein antibodies (a mean of 3.4 years before the diagnosis vs. 1.2 years, P=0.005). Anti-double-stranded DNA antibodies, with a mean onset 2.2 years before the diagnosis, were found later than antinuclear antibodies (P=0.06) and earlier than anti-nuclear ribonucleoprotein antibodies (P=0.005). For many patients, the earliest available serum sample was positive; therefore, these measures of the average time from the first positive antibody test to the diagnosis are underestimates of the time from the development of antibodies to the diagnosis. Of the 130 initial matched controls, 3.8 percent were positive for one or more autoantibodies.
Conclusions: Autoantibodies are typically present many years before the diagnosis of SLE. Furthermore, the appearance of autoantibodies in patients with SLE tends to follow a predictable course, with a progressive accumulation of specific autoantibodies before the onset of SLE, while patients are still asymptomatic.
Copyright 2003 Massachusetts Medical Society
Comment in
- Autoantibodies in systemic lupus erythematosus--there before you know it.
Shmerling RH. Shmerling RH. N Engl J Med. 2003 Oct 16;349(16):1499-500. doi: 10.1056/NEJMp038142. N Engl J Med. 2003. PMID: 14561791 No abstract available. - Autoantibodies before the clinical onset of systemic lupus erythematosus.
Kelleher P. Kelleher P. N Engl J Med. 2004 Jan 15;350(3):305; author reply 305. doi: 10.1056/NEJM200401153500320. N Engl J Med. 2004. PMID: 14724314 No abstract available.
Similar articles
- Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus.
Faria AC, Barcellos KS, Andrade LE. Faria AC, et al. J Rheumatol. 2005 Jul;32(7):1267-72. J Rheumatol. 2005. PMID: 15996063 - Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?
To CH, Petri M. To CH, et al. Arthritis Rheum. 2005 Dec;52(12):4003-10. doi: 10.1002/art.21414. Arthritis Rheum. 2005. PMID: 16320348 - Survival impact of autoantibodies in systemic lupus erythematosus.
Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS. Gulko PS, et al. J Rheumatol. 1994 Feb;21(2):224-8. J Rheumatol. 1994. PMID: 8182629 - Autoantibody determination in the diagnosis of systemic lupus erythematosus.
Kurien BT, Scofield RH. Kurien BT, et al. Scand J Immunol. 2006 Sep;64(3):227-35. doi: 10.1111/j.1365-3083.2006.01819.x. Scand J Immunol. 2006. PMID: 16918691 Review. - Antibodies to Ro and La.
Reichlin M. Reichlin M. Ann Med Interne (Paris). 1998 Feb;149(1):34-41. Ann Med Interne (Paris). 1998. PMID: 11490515 Review.
Cited by
- Screening for autoimmune diseases in apparently healthy antinuclear antibody positive individuals.
Andraos R, Ahmad A, Wirestam L, Dahle C, Frodlund M, Rönnelid J, Kastbom A, Sjöwall C. Andraos R, et al. Front Med (Lausanne). 2024 Aug 20;11:1455673. doi: 10.3389/fmed.2024.1455673. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39228805 Free PMC article. - Developing connections amongst B lymphocytes and deregulated pathways in autoimmunity.
Zouali M, Tsay G. Zouali M, et al. Mol Med. 2016 Dec;22:705-712. doi: 10.2119/molmed.2016.00206. Epub 2016 Oct 5. Mol Med. 2016. PMID: 27730250 Free PMC article. - Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.
Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P, Kahn S, Obermoser G, Blankenship D, Wakeland E, Nassi L, Gotte A, Punaro M, Liu YJ, Banchereau J, Rossello-Urgell J, Wright T, Pascual V. Banchereau R, et al. Cell. 2016 Apr 21;165(3):551-65. doi: 10.1016/j.cell.2016.03.008. Epub 2016 Mar 31. Cell. 2016. PMID: 27040498 Free PMC article. - β2-Glycoprotein I-specific T cells are associated with epitope spread to lupus-related autoantibodies.
Salem D, Subang R, Okazaki Y, Laplante P, Levine JS, Kuwana M, Rauch J. Salem D, et al. J Biol Chem. 2015 Feb 27;290(9):5543-55. doi: 10.1074/jbc.M114.619817. Epub 2015 Jan 2. J Biol Chem. 2015. PMID: 25555913 Free PMC article. - Physical characterization of the "immunosignaturing effect".
Stafford P, Halperin R, Legutki JB, Magee DM, Galgiani J, Johnston SA. Stafford P, et al. Mol Cell Proteomics. 2012 Apr;11(4):M111.011593. doi: 10.1074/mcp.M111.011593. Epub 2012 Jan 18. Mol Cell Proteomics. 2012. PMID: 22261726 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- AI24717/AI/NIAID NIH HHS/United States
- AI31584/AI/NIAID NIH HHS/United States
- AR01981/AR/NIAMS NIH HHS/United States
- AR42460/AR/NIAMS NIH HHS/United States
- AR45084/AR/NIAMS NIH HHS/United States
- AR45231/AR/NIAMS NIH HHS/United States
- AR48940/AR/NIAMS NIH HHS/United States
- AR4904/AR/NIAMS NIH HHS/United States
- RR14467/RR/NCRR NIH HHS/United States
- RR15577/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials